

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity : CurveBeam AI Limited
ABN : 32 140 706 618

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Waradana Malitha Hashan De Silva
Date of last notice	8 th May 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Investment by KP Rx Healthcare Opportunities Fund, in which Hashan De Silva is a Founder and Managing Partner
Date of change	31 st October 2024

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>Direct 565,493 ordinary shares</p> <p>124,007 Noteholder Options, with an exercise price of \$0.6720 and an expiry date of 21 August 2025</p> <p>2,058,824 Plan Options, with an exercise price of \$0.543 and expiry date of 11 May 2029</p> <p>46,875 Plan Options, with a zero exercise price, expiry date of 16 August 2029</p> <p>109,375 Plan Options with a zero exercise price, expiry date of 13th February 2030</p> <p>Indirect 320,928 ordinary shares, for HDS SMSF Pty Ltd (HDS SMSF A/C) Mr De Silva is a beneficiary</p>
<p>Class</p>	<p>Ordinary Shares</p>
<p>Number acquired</p>	<p>11,111,111</p>
<p>Number disposed</p>	<p>-</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>18c per share as part of the Placement and ANREO capital raising in August 2024, and approved at an EGM on 3rd October 2024, totalling \$1,999,999.98</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>Direct</p> <p>565,493 ordinary shares</p> <p>124,007 Noteholder Options, with an exercise price of \$0.6720 and an expiry date of 21 August 2025</p> <p>2,058,824 Plan Options, with an exercise price of \$0.543 and expiry date of 11 May 2029</p> <p>46,875 Plan Options, with a zero exercise price, expiry date of 16 August 2029</p> <p>109,375 Plan Options with a zero exercise price, expiry date of 13th February 2030</p> <p>Indirect</p> <p>320,928 ordinary shares, for HDS SMSF Pty Ltd (HDS SMSF A/C) Mr De Silva is a beneficiary</p> <p>11,111,111 ordinary shares, held by KP Rx Healthcare Opportunities Fund, Mr De Silva is a Founder and Managing Partner</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Placement approved by shareholders at EGM on 3 rd Oct 2024

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

For personal use only